Morgan Stanley’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.4M | Buy |
534,756
+19,577
| +4% | +$669K | ﹤0.01% | 3127 |
|
|
2026
Q1 | $17M | Sell |
515,179
-169,434
| -25% | -$7.17M | ﹤0.01% | 3106 |
|
|
2025
Q4 | $31.7M | Sell |
684,613
-82,807
| -11% | -$3.46M | ﹤0.01% | 2516 |
|
|
2025
Q3 | $26.9M | Buy |
767,420
+153,594
| +25% | +$5.34M | ﹤0.01% | 2599 |
|
|
2025
Q2 | $18.2M | Sell |
613,826
-22,684
| -4% | -$647K | ﹤0.01% | 2909 |
|
|
2025
Q1 | $19M | Sell |
636,510
-42,829
| -6% | -$1.31M | ﹤0.01% | 2746 |
|
|
2024
Q4 | $19.5M | Buy |
679,339
+67,608
| +11% | +$2.24M | ﹤0.01% | 2775 |
|
|
2024
Q3 | $23.6M | Sell |
611,731
-19,351
| -3% | -$690K | ﹤0.01% | 2636 |
|
|
2024
Q2 | $20.3M | Sell |
631,082
-205,862
| -25% | -$7.14M | ﹤0.01% | 2647 |
|
|
2024
Q1 | $32.5M | Sell |
836,944
-164,807
| -16% | -$5.77M | ﹤0.01% | 2173 |
|
|
2023
Q4 | $30.8M | Buy |
1,001,751
+413,286
| +70% | +$10.4M | ﹤0.01% | 2224 |
|
|
2023
Q3 | $13.2M | Buy |
588,465
+39,922
| +7% | +$911K | ﹤0.01% | 2866 |
|
|
2023
Q2 | $11.8M | Sell |
548,543
-69,814
| -11% | -$1.59M | ﹤0.01% | 3018 |
|
|
2023
Q1 | $14.8M | Buy |
618,357
+249,484
| +68% | +$6.62M | ﹤0.01% | 2746 |
|
|
2022
Q4 | $8.56M | Sell |
368,873
-46,168
| -11% | -$931K | ﹤0.01% | 3226 |
|
|
2022
Q3 | $6.65M | Buy |
415,041
+38,481
| +10% | +$679K | ﹤0.01% | 3407 |
|
|
2022
Q2 | $6.67M | Buy |
376,560
+11,230
| +3% | +$189K | ﹤0.01% | 3487 |
|
|
2022
Q1 | $7.44M | Buy |
365,330
+171,706
| +89% | +$3.24M | ﹤0.01% | 3253 |
|
|
2021
Q4 | $3.62M | Buy |
193,624
+24,273
| +14% | +$473K | ﹤0.01% | 4064 |
|
|
2021
Q3 | $3.34M | Sell |
169,351
-129,533
| -43% | -$2.8M | ﹤0.01% | 4121 |
|
|
2021
Q2 | $7.07M | Sell |
298,884
-99,372
| -25% | -$2.3M | ﹤0.01% | 3405 |
|
|
2021
Q1 | $9.44M | Buy |
398,256
+140,985
| +55% | +$3.35M | ﹤0.01% | 2718 |
|
|
2020
Q4 | $5.15M | Sell |
257,271
-52,096
| -17% | -$1.02M | ﹤0.01% | 3222 |
|
|
2020
Q3 | $6.44M | Buy |
309,367
+77,773
| +34% | +$1.4M | ﹤0.01% | 2470 |
|
|
2020
Q2 | $4.05M | Sell |
231,594
-124,777
| -35% | -$2.44M | ﹤0.01% | 2888 |
|
|
2020
Q1 | $5.82M | Sell |
356,371
-152,392
| -30% | -$3.15M | ﹤0.01% | 2308 |
|
|
2019
Q4 | $10.5M | Buy |
508,763
+22,504
| +5% | +$375K | ﹤0.01% | 2392 |
|
|
2019
Q3 | $5.58M | Sell |
486,259
-24,956
| -5% | -$285K | ﹤0.01% | 2755 |
|
|
2019
Q2 | $6.72M | Sell |
511,215
-38,987
| -7% | -$521K | ﹤0.01% | 2603 |
|
|
2019
Q1 | $8.33M | Sell |
550,202
-28,837
| -5% | -$462K | ﹤0.01% | 2211 |
|
|
2018
Q4 | $9.94M | Sell |
579,039
-477,094
| -45% | -$8.16M | ﹤0.01% | 2137 |
|
|
2018
Q3 | $15.6M | Buy |
1,056,133
+176,577
| +20% | +$3.13M | ﹤0.01% | 1920 |
|
|
2018
Q2 | $21M | Buy |
879,556
+29,903
| +4% | +$735K | 0.01% | 1601 |
|
|
2018
Q1 | $21.7M | Sell |
849,653
-64,359
| -7% | -$1.53M | 0.01% | 1593 |
|
|
2017
Q4 | $16.9M | Sell |
914,012
-16,292
| -2% | -$233K | ﹤0.01% | 1837 |
|
|
2017
Q3 | $9.76M | Buy |
930,304
+42,693
| +5% | +$471K | ﹤0.01% | 2304 |
|
|
2017
Q2 | $11.1M | Buy |
887,611
+2,343
| +0.3% | +$23.1K | ﹤0.01% | 2078 |
|
|
2017
Q1 | $8.91M | Buy |
885,268
+772,464
| +685% | +$11.5M | ﹤0.01% | 2322 |
|
|
2016
Q4 | $1.76M | Buy |
112,804
+105,080
| +1,360% | +$1.75M | ﹤0.01% | 4035 |
|
|
2016
Q3 | $150K | Sell |
7,724
-33,605
| -81% | -$399K | ﹤0.01% | 5132 |
|
|
2016
Q2 | $490K | Buy |
41,329
+13,723
| +50% | +$227K | ﹤0.01% | 4434 |
|
|
2016
Q1 | $501K | Buy |
27,606
+2,101
| +8% | +$38.2K | ﹤0.01% | 4442 |
|
|
2015
Q4 | $701K | Buy |
+25,505
| New | +$537K | ﹤0.01% | 4309 |
|
|
2015
Q3 | – | Sell |
-30,263
| Closed | -$540K | – | 6623 |
|
|
2015
Q2 | $540K | Buy |
+30,263
| New | +$523K | ﹤0.01% | 4664 |
|
Other funds holding COLL
JT
EAM
Morgan Stanley's COLL Position: Q2 2026 in Review
Morgan Stanley increased its Collegium Pharmaceutical (COLL) stake by 3.8% in Q2 2026, buying an estimated $669K and bringing the position to 534,756 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3127.
Morgan Stanley first reported a position in COLL in Q2 2015 and has held it in 44 quarters since. The position peaked at $32.5M in Q1 2024. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- Morgan Stanley held 534,756 shares of Collegium Pharmaceutical worth $19.4M as of Q2 2026.
- Morgan Stanley bought 19,577 Collegium Pharmaceutical shares in Q2 2026, an estimated $669K.
- Collegium Pharmaceutical made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3127 holding.
- Morgan Stanley first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 44 quarters since.
- Morgan Stanley's Collegium Pharmaceutical position peaked at $32.5M in Q1 2024.
- 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.